|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the gene encoding PLN have been associated with idiopathic dilated cardiomyopathy; however, no systematic search for PLN mutations in heart failure has been conducted.
|
22137083 |
2011 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, our objective was to determine the presence of the -36A>C alteration in PLN gene in a Brazilian population of individuals with HF and to test whether this alteration is associated with heart failure or with a worse prognosis of patients with HF.
|
19638213 |
2009 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abnormalities in two proteins that regulate Ca(2+) handling in myocytes, phospholamban and the voltage-dependent L-type Ca(2+) channel, were also reversed, as was the increased expression of genes that are associated with heart failure.
|
16893886 |
2006 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The potential physiological relevance of PLB function in human heart failure is also covered.
|
9790566 |
1998 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results support the development of the PLN repressor as therapy for heart failure, and provide evidence that delivery of engineered ZFP TFs to native organs can drive therapeutically relevant levels of gene repression in vivo.
|
22828502 |
2012 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the g.203A>C genetic variant in the human PLN promoter may contribute to depressed contractility and accelerate functional deterioration in heart failure.
|
18241046 |
2008 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, SANs from rabbits with HF had higher protein levels of phospholamban (PLB) and lower levels of hyperpolarization-activated cyclic nucleotide-gated potassium channel 4, ryanodine receptor and phosphorylated PLB than control SANs.
|
28352365 |
2017 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this work, we have designed and synthesized an aptamer-based near-infrared fluorescence nanoprobe for fluorescence imaging of phospholamban (PLN), which is an intracellular micropeptide that affects calcium homeostasis, and is closely associated with human heart failure in the clinic.
|
30777430 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phospholamban (PLN) inhibition enhances calcium cycling and is a potential novel therapy for heart failure (HF).
|
27811197 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phospholamban deficiency may prevent such left ventricular dysfunction and its progression to heart failure in some of the animal models with dilated cardiomyopathy.
|
11855657 |
2001 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, steady-state levels of phospholamban mRNA decreased, whereas levels of beta-myosin heavy-chain mRNA were unchanged with heart failure.
|
2040039 |
1991 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pathogenic variants in human phospholamban coding gene (PLN) are known to cause hereditary dilated cardiomyopathy with heart failure in an autosomal dominant mode.
|
30638982 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein we focus on hereditary mutants of phospholamban that are associated with heart failure, such as Arg(9)-Cys, Arg(9)-Leu, Arg(9)-His, and Arg(14)-deletion.
|
25563649 |
2015 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to reported benefits of PLN ablation in mouse heart failure, humans lacking PLN develop lethal dilated cardiomyopathy.
|
12639993 |
2003 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery.
|
12134142 |
2002 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, transgenic mice that express an inducible Galpha q mutant that cannot activate phospholipase Cbeta (PLCbeta) do not develop heart failure or changes in PLB phosphorylation, but do show decreased L-type Ca2+ current density.
|
16210321 |
2005 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, PLB, troponin I (TnI) and PP1 protein and TnI phosphorylation levels did not differ between HF and NF.
|
14732205 |
2004 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
One compound increases SERCA2a calcium affinity in cardiac membranes but not in skeletal, suggesting that the compound is acting specifically on the SERCA2a-PLB complex, as needed for a drug to mitigate deficient calcium transport in heart failure.
|
30135432 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting phospholamban by gene transfer in human heart failure.
|
11864915 |
2002 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the human G147D PPI-1 can attenuate responses of cardiomyocytes to beta-adrenergic agonists by decreasing PLN phosphorylation and therefore may contribute to deteriorated function in heart failure.
|
18192322 |
2008 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The p.Arg14del founder mutation in the gene encoding phospholamban (PLN) is associated with an increased risk of malignant ventricular arrhythmia (VA) and heart failure.
|
29635323 |
2019 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We envision a self-reinforcing mechanism beginning with phosphomimetic R9C-PLB oxidation and loss of SERCA inhibition, leading to impaired calcium regulation and heart failure.
|
25593317 |
2015 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations and post-translational modifications of PLN may lead to dilated cardiomyopathy (DCM) and heart failure.
|
29501609 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The data demonstrate an association between the dose-dependent inhibition of SERCA2a activity by PLN(wt) and the time of onset of heart failure and show that a weak inhibitor of SERCA2a, PLN(R9C), which is diminished in its ability to modify the level of SERCA2a activity, leads to heart failure despite fast sarcoplasmic reticulum Ca(2+) reuptake.
|
19139388 |
2009 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that PLN deletion would be a promising approach to improve both mortality and cardiac function in the heart failure.
|
27992596 |
2016 |